News
SOURCE: Biolog, Inc. The post Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence ...
The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.
The drug failed to meet its primary endpoints in clinical trials, but subgroup analyses hinted at modest benefits.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, KalVista ...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, Ionis ...
22h
MedPage Today on MSNUnwelcome Data on GLP-1 Agonists; Growth Hormone Drug for Adults; Top Endo HospitalsAnother study linked GLP-1 receptor agonist use with higher odds of developing nonarteritic anterior ischemic optic ...
"Tevimbra is already approved in the EU across multiple settings in [non-small cell lung cancer], the most common form of lung cancer, and this positive CHMP opinion expands its potential to help ...
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...
The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...
The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.
The agency weighed safety data and a new dosing regimen to recommend approval of the treatment for early Alzheimer's disease in certain patients.
Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results